$ARWR VRTX is in more trouble than BofA is projecting. Their AAT program is way behind ARWR/Takeda, which will have Orphan Drug exclusivity to block VRTX even if their second trial doesn't fail... It's now clear that Leerink's orchestrated short attack on ARWR has run it's course, and Mani Foorohar's (aka FUBAR) latest short thesis have blown up in his face. Mani is now just a road kill speed bump for ARWR.
  • 6